Neuroscape is an eight-year effort led by its founder and executive director Adam Gazzaley, MD, PhD, who is also an Akili board member. He says the labs’ goals are to find personalized treatment approaches with fewer side effects for neurological disorders.
“Our brain’s plasticity, its ability to modify itself, really responds to experience,” Dr. Gazzaley told CNBC. “If we can create very targeted experiences that are also adaptive to a person, it can help improve their brain function.”
One of Akili’s games, called “Project: EVO,” is at the last level of Food and Drug Administration approval for the treatment of attention deficit hyperactivity disorder. The lab has also partnered with Pfizer to study how its games can detect signs of Alzheimer’s disease.
More articles on population health:
California: Pathologists must report cancer diagnoses to electronic registry by 2019
Virginia Tech researchers examine environmental health disparities in Appalachia
Housing instability will cost healthcare industry $111B over next decade
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.